With Kova, buying access to a weight-management program and receiving medical care are related but separate transactions. LifeTech Apps Inc operates the technology platform; independent medical groups make clinical decisions, and pharmacies handle medication fulfillment. That separation matters at every step: who approves a prescription, who answers a medication question, what happens when a shipment is delayed, and whether a subscription payment means a refill is ready.
This review follows those handoffs using public documentation consulted October 19, 2026. Kova advertises access to compounded semaglutide and tirzepatide, delivery, clinician consultations and a companion app within subscription plans. The documentation is reasonably specific about initial payment authorization and patient contact routes. It is less complete about exact products, follow-up schedules and longer-plan obligations, while the available terms excerpt cuts off within the financial provisions needed to evaluate cancellation and refunds fully.
At a glance
- Who provides care
- LifeTech Apps Inc operates Kova’s platform and says it does not provide medical, pharmacy or laboratory services; independent medical groups provide clinical care.Sources: [4]
- Advertised medicines
- Kova advertises access to compounded semaglutide and tirzepatide subject to clinical evaluation, provider approval, state availability and pharmacy availability.Sources: [3]
- Initial versus recurring charges
- Initial payment capture requires clinical eligibility and an initial prescription, but subsequent scheduled charges may precede clinical review or prescription renewal.Sources: [4]
- Included and separate services
- Kova says subscriptions include consultations, fulfillment, medication delivery, support and app access, with no separate medication charge. Required laboratory work costs extra.Sources: [3]
Start by identifying the organization responsible for each step
Kova is the platform name, not the name of a single organization performing every service. Its terms identify LifeTech Apps Inc as the operator of the mobile application, website, accounts, portals and enrollment flows. The site lists a Wilmington, Delaware registered office. More importantly for patients, the company expressly separates its technology services from medical, pharmacy and laboratory services. Clinical decisions belong to independent medical provider groups and their licensed healthcare professionals.
The website describes a relationship with Telegra’s provider network and names Laurie Mercier, MD, and nurse practitioners Kimberli Hastings, Theresa Vergara and Craig Sorkin. These are provider-published descriptions, not independently verified credentials or a promise that a particular professional will handle an individual’s care. Before enrollment, ask which medical group will hold the clinical relationship and which clinician will review the intake, particularly if continuity with the same professional matters.
This division of responsibilities is useful only if patients can navigate it. Kova supplies separate routes for app questions and medical questions, while the pharmacy has its own responsibilities after prescribing. Our guide to the difference between a clinician and a platform explains the distinction. For Kova specifically, preserve the assigned medical group’s name and pharmacy contact information rather than assuming the general brand support address handles every problem.
Intake begins online, but approval remains a clinical decision
Kova describes a short questionnaire covering goals, medical history and treatment preferences, including injectable versus oral treatment. A licensed clinician then reviews the intake, history and goals online to decide whether GLP-1 treatment is appropriate. The site says no medication ships without provider approval. It does not establish whether every patient receives a live appointment, how quickly review occurs, or the precise medical eligibility criteria used by the assigned group.
Platform eligibility is clearer than treatment eligibility. Users must be at least 18, legally able to enter a binding contract and located in the United States. When receiving clinical services, they must physically be in a state or territory where the applicable professional is authorized to practice. Kova advertises support across all 50 states, but qualifies specific services by professional licensure and state regulations. That is not an unconditional promise of every medicine in every state.
People already taking a GLP-1 must still complete the medical intake. Kova says a clinician reviews their current treatment and history before deciding whether care can continue or transition. Existing use therefore does not establish automatic acceptance, an unchanged prescription or immediate shipment. Preparing a current medication history and questions about continuity is more useful than treating enrollment as a transfer guarantee; the documentation supplies no fixed transition timetable.
Confirm the actual prescription before interpreting the offer
The advertised drug options are compounded semaglutide and tirzepatide, with availability dependent on state, pharmacy capacity and provider judgment. Although the intake asks about oral or injectable preferences, that question does not confirm which formulations are actually offered by each route. The reviewed documentation does not establish concentrations, presentations or the amount supplied per shipment. An ingredient name and plan duration are not enough to identify the product a patient would receive.
Kova’s terms acknowledge that compounded medicines are not FDA approved, are not reviewed by FDA for safety, effectiveness or quality before marketing, and are not FDA-approved generics. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, but neither does it establish equivalence to an approved product or validate this particular program.
Ask the prescriber to identify the prescribed formulation, route and presentation, and ask the dispensing pharmacy to confirm the label and instructions. Our product, route and pharmacy checklist organizes those questions. FDA has reported measurement and administration errors involving compounded medicines, including some associated with hospitalization. The appropriate response is clear, product-specific instruction from the prescriber or pharmacist—not calculating an individual dose from a review, advertisement or another patient’s experience.
The subscription bundles services, but billing follows its own clock
Kova says subscriptions cover clinician consultations, prescription fulfillment, medication delivery, ongoing support and full companion-app access, without a separate medication charge. Laboratory testing is an explicit exception: a clinician may order and review tests, but patients pay separately if testing is required. Insurance is not required, and advertised pricing is the same regardless of insurance status. Kova directs people considering FSA or HSA reimbursement to their plan administrator; that is not confirmation of reimbursement eligibility.
The one-month semaglutide offer is $249 for the first month, then $299 per month. The one-month tirzepatide offer is $299 initially, then renews at $399; that particular line does not restate the renewal interval. Longer plans offer monthly or upfront payment alternatives, not mandatory upfront collection. None of these durations establishes how much medicine arrives at once, and the incomplete terms prevent a firm conclusion about minimum commitments or early-exit obligations.
For initial enrollment, the terms permit a temporary authorization hold but say payment will not be captured until a provider finds the patient eligible and issues the first prescription. Without that prescription, the hold is released or voided. Later charges work differently: scheduled recurring payments may occur before subsequent reviews, refill requests or prescription renewals are complete. Checkout terms and the order confirmation control conflicting general economic terms, so retain those documents before authorizing payment.
| Plan duration | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| 1 month | $249 first month; then $299/month | $299 first month; then $399, renewal interval not restated |
| 3 months | $179/month or $537 upfront | $249/month or $747 upfront |
| 6 months | $149/month or $894 upfront | $229/month or $1,374 upfront |
| 12 months | $129/month or $1,548 upfront | $199/month or $2,388 upfront |
The pharmacy handoff needs a patient-specific name
Kova attributes a nationwide network of 503a and 503b compounding pharmacies to Telegra MD LLC. The site’s pharmacy-provider list includes E-RxHub, Absolute Pharmacy, Southend Pharmacy, Strive Pharmacy and Pharmacy Boudreaux’s. Those listings document possible contacts, not which pharmacy will compound or dispense a particular patient’s prescription. This review did not independently verify the network classification, professional licenses or the allocation of orders among the listed organizations.
The published contacts include E-RxHub at (800) 311-5805 and support@e-rxhub.com; Southend Pharmacy at (855) 414-5356 and info@southendpharmacystore.com; and Pharmacy Boudreaux’s at (318) 299-1092 and questions@boudreauxscompounding.com. Absolute Pharmacy lists support@absoluterx.com, while Strive Pharmacy lists info@strivepharmacy.com. These can help identify the appropriate channel once the assigned pharmacy is known, but the directory alone does not confirm that an organization has received a prescription.
Before expecting a delivery, ask for the actual dispensing pharmacy’s name, prescription status and product details. Kova describes fulfillment coordination as part of the plan, yet the reviewed pages do not provide a numeric pharmacy-processing deadline or establish supply quantity per shipment. A three-, six- or twelve-month subscription should not be read as a promise that the entire period’s medication will be dispensed in one package or that dispensing has already occurred.
Shipping estimates are not arrival guarantees
Kova’s terms make shipping and delivery dates estimates, subject to clinical review, pharmacy processing, product availability, carrier operations and other circumstances outside the company’s reasonable control. The documentation provides no separate numeric deadlines for approval, preparation, dispatch and arrival. Those stages should not be collapsed into a single delivery promise. The patient portal offers delivery tracking, but a tracking function does not mean a prescription is approved or a parcel has reached the patient.
Patients must provide an accurate address, update it before shipment, retrieve the package promptly and store it as instructed by the pharmacy. Subject to applicable law, the terms treat a shipment as delivered once the carrier confirms delivery to that address. For an approved shipping claim, Kova may arrange a replacement without an additional charge or, if replacement is not reasonably available, provide an applicable credit or refund under the governing terms.
That remedy is conditional, not an automatic refund for every delivery problem. Dispensed products are not returnable unless the pharmacy directs otherwise. For injectable GLP-1 medication arriving warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. Our guide to FDA advice on warm injectable deliveries provides context. Ask the assigned pharmacy how to report a questionable shipment rather than assuming carrier confirmation resolves its condition.
Follow-up tools do not establish continuous monitoring
Through the provider portal, patients can securely message their clinician, request refills, track delivery and manage billing. Kova advertises the medical provider’s patient support as available 24/7, but the documentation does not specify a guaranteed response time. General questions about the companion app go to support@trykova.com; medication, prescription, refill and medical-care questions belong in the patient portal. Using the correct channel matters when an answer is needed before the next shipment or renewal.
The companion app is included at no extra cost and is described as offering reminders, injection-site records, symptom tracking, protein tracking, history and education, with features subject to change. However, the general plan description qualifies ongoing check-ins as provided where applicable. It does not establish a standard appointment schedule, mandatory refill assessment or consistent clinician assignment. Readers comparing support promises can use our guide to what ongoing GLP-1 support means to frame concrete questions.
The terms expressly disclaim continuous monitoring of health, symptoms, medication use or platform activity. Messages, symptom check-ins and reminders do not make Kova an emergency service. Separately, the consumer health data notice permits operational sharing with AM APPS LTD, an affiliate outside the United States, subject to stated contractual and legal protections. A document served at a telehealth-consent address was actually titled Consumer Health Data Privacy Notice; it should not be mistaken for medical consent.
Plan the end of service as carefully as enrollment
Kova’s website says cancellation can be requested through the account page or support team. Its more specific explanation says access ends after the paid period, including the active medication plan, upcoming refills, clinical care through the platform and the companion app. Restarting later may require a new clinical evaluation. That describes an access boundary, but does not establish a right to recover unused payments or explain every consequence of ending a longer-duration plan.
The available terms excerpt omits text beginning within the financial provisions, preventing reconstruction of the complete general cancellation and refund rules. Checkout conditions, order confirmations and separate clinical or pharmacy terms were not reviewed. Before choosing a longer plan, request the cancellation procedure, any renewal notice deadline, remaining payment obligations and refund boundaries in writing. The public statement that cancellation is available at any time cannot answer all of those questions by itself.
Continuity also requires distinguishing a stopped subscription from a completed care transition. Recurring billing can precede clinical renewal, and cancellation eventually removes clinical and app access. Ask how to obtain records, resolve an outstanding prescription request and coordinate any future care before the paid period ends. These are service-planning questions, not instructions to stop or adjust medicine. The useful outcome is a documented next step with the responsible clinician, rather than an assumption that billing changes settle clinical responsibilities.
Questions & answers
Does Kova guarantee a prescription after I enroll?
No. A licensed clinician reviews the intake and determines appropriateness. The terms allow an initial authorization hold, but say the first plan charge is captured only after eligibility and an initial prescription. If no initial prescription is issued, the hold is released or voided. That initial safeguard does not govern later recurring charges in the same way.
Can I choose oral semaglutide or tirzepatide through Kova?
The intake asks about oral versus injectable preferences, but the reviewed pages do not confirm the exact medicine, formulation or presentation available through each route. Treat the preference question as intake information, not a product guarantee. Ask the prescriber which specific preparation is proposed and which pharmacy would dispense it before interpreting the advertised price as an offer for that product.
Are laboratory tests included in the subscription?
No. Kova says a clinician can order testing and review results when needed, but laboratory work is paid separately. The subscription otherwise advertises consultations, prescription fulfillment, medication delivery, support and app access, without a separate medication charge. Ask about any anticipated testing expense during clinical review; the public documentation does not supply a laboratory price schedule.
Who should I contact about a refill or medication problem?
Use the patient portal for medication, prescription, refill and medical-care questions. Kova reserves support@trykova.com for general companion-app inquiries. The portal also supports secure provider messaging and refill requests. Although the website advertises 24/7 medical-provider support, it does not promise a specific response interval, and the terms say the service is not continuously monitored or intended for emergencies.
Does a twelve-month plan mean twelve months of medicine arrive together?
The documentation does not establish that. It lists twelve-month pricing alternatives, but plan duration and billing frequency do not establish shipment quantity or dispensing frequency. Kova also separates billing from clinical review, prescriptions, refills and shipments. Request the expected fulfillment schedule and supply quantity from the assigned provider and pharmacy rather than inferring either from the plan label.
Will canceling Kova produce a refund?
The reviewed documentation does not establish a general refund entitlement. The website allows cancellation through the account page or support and says access ends after the paid period. However, the available terms excerpt is incomplete where important financial rules appear. Obtain the applicable plan terms and written confirmation of cancellation timing, remaining obligations and any refund before assuming unused time will be reimbursed.
Our assessment
Kova documents a recognizable care pathway: online intake, independent clinical review, coordinated pharmacy fulfillment, delivery and portal-based support. Its bundled prices and distinction between initial authorization and payment capture are useful disclosures. The main weaknesses are unresolved operational details: exact formulations, patient-specific pharmacy assignment, follow-up cadence, shipment quantities and complete longer-plan cancellation terms. Recurring payments can also run ahead of clinical renewal. Before enrolling, obtain the actual product description, assigned care contacts, refill process and governing checkout terms. Those answers—not app features or nationwide-access language alone—will determine how understandable and manageable the service is.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.